Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R01) | Apply Online

Opportunity Summary:

The NIH funding opportunity "Eradication of HIV-1 from CNS Reservoirs: Implications for Therapeutics (R01)" (Funding Opportunity Number RFA-MH-14-170) was designed to push the field beyond the well-studied blood and lymphoid HIV reservoirs and focus tightly on a harder problem: why HIV-1 can persist in the central nervous system (CNS) even when a person is on effective, suppressive Highly Active Antiretroviral Therapy (HAART). The core idea behind the announcement is that long-term viral persistence in the brain and related CNS compartments may involve different cell types, different biology, and different clinical risks than persistence elsewhere in the body. Because the CNS is protected by specialized barriers, has unique immune dynamics, and contains long-lived resident cells, it is not automatically safe to assume that strategies aimed at clearing HIV from peripheral reservoirs will translate cleanly to the brain. This FOA sought research that would clarify what the CNS reservoir actually looks like, how it is established and maintained, and how eradication efforts might work (or fail) in this compartment, including potential harms.

The FOA prioritized five main research directions. First, it encouraged basic studies that directly identify and characterize persistent HIV-1 in CNS-derived cells in people on suppressive therapy. Particular attention was placed on macrophages, microglia, and astrocytes because these cell populations are biologically plausible sites of persistence and are central to neuroinflammation and neurologic disease. Importantly, the announcement explicitly allowed the work to consider CNS persistence both with and without substance use, reflecting real-world conditions and the possibility that chronic drug exposure may alter immune function, CNS inflammation, or viral dynamics in ways that affect reservoir formation and stability.

Second, the FOA called for mechanistic research on how persistent HIV-1 is established over time, how it is maintained, and how it might rebound or resurge, with special emphasis on the timing of antiretroviral therapy. This includes questions such as whether very early treatment changes the likelihood of seeding a durable CNS reservoir, whether late initiation leaves behind more entrenched infection in resident CNS cells, and which molecular or immunologic pathways drive long-term maintenance or intermittent reactivation. In other words, it aimed to connect clinical timelines (when therapy starts, how long suppression lasts) to the biology of latency and persistence in the CNS.

Third, the announcement supported the creation and refinement of physiologically relevant models and assays that reproduce CNS HIV persistence under conditions that resemble effective treatment. That includes animal models and CNS-based cellular systems that can mimic latency or low-level persistence in the presence of suppressive HAART, not simply acute infection. The FOA also highlighted the value of models that incorporate the effects of chronic substance use, since substance exposure may affect blood-brain barrier function, microglial activation, treatment adherence patterns, or drug penetration into the CNS. The emphasis on "physiologically relevant" reflects a practical need: eradication strategies are difficult to evaluate without models that realistically capture CNS compartment biology.

Fourth, the FOA asked investigators to test current and emerging eradication approaches specifically for their ability to reactivate or expose persistent HIV in CNS-derived cells such as macrophages, microglia, and astrocytes. This focus is important because many eradication concepts (for example, "shock and kill" or other latency-reversing approaches) have been largely evaluated in peripheral blood cells, especially CD4+ T cells. The NIH was looking for evidence about whether these strategies actually reach the CNS reservoir, whether they can induce viral expression in relevant CNS cell types, and what the measurable outcomes should be when the target is the brain rather than the blood.

Fifth, the FOA underscored the need to evaluate CNS toxicity and other adverse impacts of eradication strategies. Even if an approach is effective at reactivating latent virus, the brain is a high-stakes environment where inflammation, excitotoxicity, glial activation, or off-target drug effects could cause cognitive or neurologic harm. This part of the program recognized that eradication efforts could carry unique risks in the CNS, so safety and neurotoxicity assessments were not an afterthought but a dedicated research priority.

From a practical grants perspective, this was an NIH R01 mechanism (a standard research project grant) under the discretionary grant category, with no cost-sharing or matching requirement. The opportunity was posted April 10, 2013, and had an original and current closing date of September 17, 2013, with an archive date of October 18, 2013. The estimated total funding amount listed was $1.5 million. The program spanned multiple NIH-relevant research domains reflected in the CFDA listings, including mental health research, drug abuse and addiction programs, neurosciences and neurological disorders, allergy and infectious diseases, and microbiology/infectious diseases. That mix signals how the FOA framed CNS HIV persistence as simultaneously a virology problem, a neurology problem, and, in many cases, a substance-use and behavioral health problem.

Eligibility was broad and included many types of U.S. organizations and government entities (state, county, city/township governments; special district governments; public and private institutions of higher education; independent school districts; public housing authorities/Indian housing authorities; tribal governments and tribal organizations; nonprofits with or without 501(c)(3) status; small businesses; and for-profit organizations other than small businesses). The FOA also made clear that non-U.S. entities were eligible, including foreign organizations and foreign institutions, as well as non-domestic components of U.S. organizations, and that foreign components (as defined by NIH policy) were allowed. The announcement explicitly welcomed applications across the spectrum from basic to translational research, in both domestic and international settings. While it encouraged multidisciplinary teams, it did not require them, leaving room for focused single-lab efforts as well as broader collaborative projects.

In short, this FOA was a targeted call to treat the CNS as its own critical battleground in HIV cure and eradication research. It aimed to map and understand HIV persistence in CNS-resident or CNS-associated cell types under suppressive therapy, build better models to study that persistence, test whether eradication tools truly work in the brain, and make sure that any proposed cure strategies are evaluated for neurologic safety rather than judged solely by peripheral blood outcomes.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R21)

Previous opportunity: BJA FY 13 Law Enforcement National Training and Technical Assistance

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA MH 14 170

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA MH 14 170) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 14 170", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.